These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1080 related articles for article (PubMed ID: 9886380)
21. MHC class II presentation of endogenously expressed antigens by transfected dendritic cells. Diebold SS; Cotten M; Koch N; Zenke M Gene Ther; 2001 Mar; 8(6):487-93. PubMed ID: 11313828 [TBL] [Abstract][Full Text] [Related]
22. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway. Rock KL; Clark K J Immunol; 1996 May; 156(10):3721-6. PubMed ID: 8621907 [TBL] [Abstract][Full Text] [Related]
23. Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. Breckpot K; Dullaers M; Bonehill A; van Meirvenne S; Heirman C; de Greef C; van der Bruggen P; Thielemans K J Gene Med; 2003 Aug; 5(8):654-67. PubMed ID: 12898635 [TBL] [Abstract][Full Text] [Related]
24. [Enhanced translational efficacy of internal ribosomal entry site-mediated mRNA in dendritic cells contributes to efficient induction of antitumor immunity]. Tan XH; Wan YH Zhonghua Yi Xue Za Zhi; 2007 Feb; 87(6):399-403. PubMed ID: 17456382 [TBL] [Abstract][Full Text] [Related]
25. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo. Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016 [TBL] [Abstract][Full Text] [Related]
26. A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses. You Z; Hester J; Rollins L; Spagnoli GC; van der Bruggen P; Chen SY Cancer Res; 2001 Jan; 61(1):197-205. PubMed ID: 11196161 [TBL] [Abstract][Full Text] [Related]
27. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs. Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753 [TBL] [Abstract][Full Text] [Related]
28. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169 [TBL] [Abstract][Full Text] [Related]
29. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells. Sun JB; Eriksson K; Li BL; Lindblad M; Azem J; Holmgren J Clin Immunol; 2004 Jul; 112(1):35-44. PubMed ID: 15207780 [TBL] [Abstract][Full Text] [Related]
30. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory. Hao S; Yuan J; Xiang J J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150 [TBL] [Abstract][Full Text] [Related]
31. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Reeves ME; Royal RE; Lam JS; Rosenberg SA; Hwu P Cancer Res; 1996 Dec; 56(24):5672-7. PubMed ID: 8971174 [TBL] [Abstract][Full Text] [Related]
32. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Dullaers M; Van Meirvenne S; Heirman C; Straetman L; Bonehill A; Aerts JL; Thielemans K; Breckpot K Gene Ther; 2006 Apr; 13(7):630-40. PubMed ID: 16355115 [TBL] [Abstract][Full Text] [Related]
33. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy. Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722 [TBL] [Abstract][Full Text] [Related]
34. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. Labeur MS; Roters B; Pers B; Mehling A; Luger TA; Schwarz T; Grabbe S J Immunol; 1999 Jan; 162(1):168-75. PubMed ID: 9886383 [TBL] [Abstract][Full Text] [Related]
35. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide. Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399 [TBL] [Abstract][Full Text] [Related]
36. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells. Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057 [TBL] [Abstract][Full Text] [Related]
37. RNA-containing adenovirus/polyethylenimine transfer complexes effectively transduce dendritic cells and induce antigen-specific T cell responses. Gust TC; Diebold SS; Cotten M; Zenke M J Gene Med; 2004 Apr; 6(4):464-70. PubMed ID: 15079821 [TBL] [Abstract][Full Text] [Related]
38. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes. Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194 [TBL] [Abstract][Full Text] [Related]
39. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells. Ribas A; Butterfield LH; Amarnani SN; Dissette VB; Kim D; Meng WS; Miranda GA; Wang HJ; McBride WH; Glaspy JA; Economou JS Cancer Res; 2001 Dec; 61(24):8787-93. PubMed ID: 11751400 [TBL] [Abstract][Full Text] [Related]
40. Impaired ability of MHC class II-/- dendritic cells to provide tumor protection is rescued by CD40 ligation. Hermans IF; Ritchie DS; Daish A; Yang J; Kehry MR; Ronchese F J Immunol; 1999 Jul; 163(1):77-81. PubMed ID: 10384102 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]